CASI Pharmaceuticals (CASIF) Net Income towards Common Stockholders (2022 - 2025)

CASI Pharmaceuticals has reported Net Income towards Common Stockholders for 4 years, with the latest figure at -$77.2 million in Q4 2025.

• For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 459.98% year-over-year to -$77.2 million; the trailing twelve-month figure through Dec 2025 stood at -$109.4 million (down 162.59% YoY), and the FY2025 full-year result was -$45.9 million, down 801.38% from the prior year.
• Net Income towards Common Stockholders for Q4 2025 stood at -$77.2 million, down from -$10.0 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $16.1 million in Q4 2023, with the low at -$77.2 million in Q4 2025.
• Historically, Net Income towards Common Stockholders has averaged -$16.1 million across 4 years, with a median of -$9.5 million in 2023.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders surged 132.94% — and 2025, when it sank 459.98%.
• CASI Pharmaceuticals' Net Income towards Common Stockholders stood at -$48.9 million in 2022, then surged by 132.94% to $16.1 million in 2023, then tumbled by 185.53% to -$13.8 million in 2024, then slumped by 459.98% to -$77.2 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$77.2 million (Q4 2025), -$10.0 million (Q3 2025), and -$11.6 million (Q2 2025), per Business Quant data.